| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT00083486 |
Purpose
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.
| Condition | Intervention | Phase |
|
Anemia |
Drug: epoetin alfa |
Phase III |
| MedlinePlus related topics: | Anemia Cancer |
| Drug Information available for: | Epoetin alfa Erythropoietin |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| United States, Arkansas | |||||
| Heritage Physician Group-Oncology | |||||
| Hot Springs, Arkansas, United States, 71913 | |||||
| United States, Georgia | |||||
| Spalding Oncology Services | |||||
| Griffin, Georgia, United States, 30224 | |||||
| United States, Illinois | |||||
| Southern Illinois Hematology | |||||
| Centralia, Illinois, United States, 62801 | |||||
| United States, Maryland | |||||
| BioLab Research | |||||
| Rockville, Maryland, United States, 20852 | |||||
| United States, New York | |||||
| Slocum-Dickson Medical Group, PC | |||||
| New Hartford, New York, United States, 13413 | |||||
| United States, North Carolina | |||||
| NorthEast Urology Research | |||||
| Concord, North Carolina, United States | |||||
| United States, Ohio | |||||
| Mid Ohio Oncology Hematology | |||||
| Columbus, Ohio, United States, 43213 | |||||
| United States, Pennsylvania | |||||
| Drexel University College of Medicine | |||||
| Philadelphia, Pennsylvania, United States, 19102 | |||||
| United States, South Carolina | |||||
| Charleston Cancer Care | |||||
| Charleston, South Carolina, United States, 29406 | |||||
| Charleston Hematology Oncology | |||||
| Charleston, South Carolina, United States, 29403 | |||||
| Caroline Cancer Center | |||||
| Aiken, South Carolina, United States, 29403 | |||||
| United States, Tennessee | |||||
| Volunteer Research Group | |||||
| Knoxville, Tennessee, United States, 37920 | |||||
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
More Information
| Study ID Numbers: | EPO-CAN-203 |
| First Received: | May 24, 2004 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00083486 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
